Natera, Inc. $NTRA Shares Sold by GW&K Investment Management LLC

GW&K Investment Management LLC trimmed its position in Natera, Inc. (NASDAQ:NTRA) by 3.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 413,474 shares of the medical research company’s stock after selling 15,035 shares during the quarter. GW&K Investment Management LLC’s holdings in Natera were worth $66,558,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of NTRA. JPMorgan Chase & Co. raised its holdings in Natera by 44.3% in the second quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock valued at $1,795,125,000 after buying an additional 3,263,822 shares during the period. Norges Bank acquired a new stake in shares of Natera in the second quarter worth $277,749,000. AQR Capital Management LLC raised its stake in shares of Natera by 44.6% in the 2nd quarter. AQR Capital Management LLC now owns 1,726,750 shares of the medical research company’s stock valued at $291,717,000 after acquiring an additional 532,769 shares during the period. Franklin Resources Inc. raised its stake in shares of Natera by 20.6% in the 2nd quarter. Franklin Resources Inc. now owns 1,937,647 shares of the medical research company’s stock valued at $327,346,000 after acquiring an additional 330,696 shares during the period. Finally, Holocene Advisors LP lifted its holdings in shares of Natera by 118.3% during the 2nd quarter. Holocene Advisors LP now owns 572,832 shares of the medical research company’s stock valued at $96,774,000 after acquiring an additional 310,452 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Stock Down 1.9%

Shares of NASDAQ NTRA opened at $203.03 on Thursday. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The business has a 50 day moving average price of $224.59 and a two-hundred day moving average price of $204.76. The firm has a market cap of $28.78 billion, a PE ratio of -132.70 and a beta of 1.65.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.46) by $0.81. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The company had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. During the same period in the prior year, the business posted ($0.41) EPS. On average, analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NTRA has been the subject of several recent research reports. Guggenheim increased their price target on Natera from $230.00 to $270.00 and gave the company a “buy” rating in a report on Monday, January 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Thursday, January 22nd. Piper Sandler boosted their price target on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Robert W. Baird increased their price objective on shares of Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. Finally, Canaccord Genuity Group reiterated a “buy” rating on shares of Natera in a research note on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $253.47.

Insider Activity

In other Natera news, CEO Steven Leonard Chapman sold 85,299 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $230.72, for a total transaction of $19,680,185.28. Following the completion of the transaction, the chief executive officer directly owned 127,881 shares of the company’s stock, valued at $29,504,704.32. This trade represents a 40.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Solomon Moshkevich sold 23,205 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total transaction of $5,447,141.70. Following the completion of the sale, the insider owned 144,992 shares in the company, valued at approximately $34,035,422.08. This trade represents a 13.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 367,669 shares of company stock worth $85,584,453 over the last ninety days. Insiders own 5.63% of the company’s stock.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Signatera is being highlighted as a primary growth driver for Natera’s oncology business, supporting revenue momentum and investor optimism about recurring MRD testing demand. Signatera Oncology Test Drives Natera’s (NTRA) Growth
• Positive Sentiment: Management presented at TD Cowen’s healthcare conference; the transcript emphasizes commercial progress across oncology (Signatera), reproductive health and transplant products, reinforcing the narrative behind recent revenue beats. Natera Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Positive Sentiment: Coverage noting why the stock traded up ties the move to the company’s recent operational beats and growth commentary, which can amplify buying interest on upside news. Natera (NTRA) Stock Trades Up, Here Is Why
• Neutral Sentiment: Morgan Stanley trimmed its price target from $265 to $250 but kept an Overweight rating — a modestly negative signal on price scope but still reflects continued analyst confidence. Morgan Stanley Lowers Price Target
• Neutral Sentiment: MarketBeat/analyst notes show a consensus “Moderate Buy” and a cluster of raised targets from other firms, indicating mixed but generally constructive analyst sentiment that could limit downside. NTRA MarketBeat Summary
• Negative Sentiment: Insider selling: CEO Steven Chapman and longtime insider Solomon Moshkevich sold shares in early March (transactions near $200/sh), which can weigh on sentiment even if the trades appear to be routine liquidity. Natera Insider Sells $599,550.00 in Stock

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.